Quest Laboratories Ltd. ((IN:QUESTLAB)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Quest Laboratories Ltd. is currently involved in a clinical study titled A Phase 1, Open Label, Dose-Escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of a Nanoparticle Carrier-Formulated Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever (HDT-321) in Healthy Adults. The study aims to assess the safety and effectiveness of the HDT-321 vaccine in preventing Crimean-Congo hemorrhagic fever, a significant viral threat. This research is crucial for developing new preventive measures against this virus.
The intervention being tested is the HDT-321 vaccine, a nanoparticle carrier-formulated self-amplifying RNA vaccine. It is designed to provide immunity against the Crimean-Congo hemorrhagic fever virus by inducing an immune response in healthy adults.
The study follows an interventional design with a non-randomized, parallel assignment. It involves four groups of 12 participants each, receiving varying doses of the vaccine. There is no masking, and the primary purpose is prevention.
The study began on January 16, 2025, with the latest update on July 23, 2025. These dates are significant as they mark the progress and current status of the study, which is still recruiting participants.
The update on this study could positively impact Quest Laboratories Ltd.’s stock performance by boosting investor confidence in the company’s innovative research efforts. In the competitive vaccine market, advancements in RNA vaccine technology could position Quest Laboratories favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.